Progress in the treatment and management of tuberculosis complicated with diabetes

doi:10.3969/j.issn.1000-6621.2021.01.016

Abstract

Abstract:

It is estimated that the number of patients with diabetes mellitus (DM) may increase to 700 million by 2045 in the world, and about 16% of tuberculosis patients may have DM, so the double burden caused by tuberculosis complicated with diabetes mellitus (TB-DM) will become a major global public health problem. Diabetes (including type 1 and type 2) can increase the risk of getting active tuberculosis. Compared with the patients who only have tuberculosis, the patients with TB-DM have worse treatment outcomes. Therefore, the increasing incidence of diabetes will not only increase the risk of having tuberculosis, but also pose a serious challenge to the treatment and management of tuberculosis. In this article, the authors reviewed the following issues related to TB-DM: the two-way screening, interactions of the two diseases, treatment and management, and drug interactions, etc.

Key words: Tuberculosis, Diabetes mellitus, Comorbidity, Practice management,medical, Drug therapy,combination, Drug interactions, Review

YANG Min, FU Liang, DENG Guo-fang. Progress in the treatment and management of tuberculosis complicated with diabetes[J]. Chinese Journal of Antituberculosis, 2021, 43(1): 87-90. doi: 10.3969/j.issn.1000-6621.2021.01.016

References 35

[1]	World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
[2]	Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract, 2018,138:271-281. doi: 10.1016/j.diabres.2018.02.023. doi: 10.1016/j.diabres.2018.02.023 URL pmid: 29496507
[3]	Workneh MH, Bjune GA, Yimer SA. Prevalence and associa-ted factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. PLoS One, 2017,12(4):e0175925. doi: 10.1371/journal.pone.0175925. doi: 10.1371/journal.pone.0175925 URL pmid: 28430796
[4]	Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol, 2014,44(3):617-626. doi: 10.1002/eji.201344301. URL pmid: 24448841
[5]	Jiménez-Corona ME, Cruz-Hervert LP, García-García L, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax, 2013,68(3):214-220. doi: 10.1136/thoraxjnl-2012-201756. doi: 10.1136/thoraxjnl-2012-201756 URL pmid: 23250998
[6]	Viswanathan V, Kumpatla S, Aravindalochanan V, et al. Prevalence of diabetes and pre-diabetes and associated risk factors among tuberculosis patients in India. PLoS One, 2012,7(7):e41367. doi: 10.1371/journal.pone.0041367. doi: 10.1371/journal.pone.0041367 URL pmid: 22848473
[7]	Lee PH, Fu H, Lai TC, et al. Glycemic Control and the Risk of Tuberculosis: A Cohort Study. PLoS Med, 2016,13(8):e1002072. doi: 10.1371/journal.pmed.1002072. doi: 10.1371/journal.pmed.1002072 URL pmid: 27505150
[8]	Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2·3 million patients with tuberculosis. Lancet Glob Health, 2019,7(4):e448-460. doi: 10.1016/S2214-109X(18)30487-X. doi: 10.1016/S2214-109X(18)30487-X URL pmid: 30819531
[9]	Boillat-Blanco N, Ramaiya KL, Mganga M, et al. Transient Hyperglycemia in Patients With Tuberculosis in Tanzania: Implications for Diabetes Screening Algorithms. J Infect Dis, 2016,213(7):1163-1172. doi: 10.1093/infdis/jiv568. doi: 10.1093/infdis/jiv568 URL pmid: 26609005
[10]	Grint D, Alisjhabana B, Ugarte-Gil C, et al. Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa. Bull World Health Organ, 2018,96(11):738-749. doi: 10.2471/BLT.17.206227. doi: 10.2471/BLT.17.206227 URL pmid: 30455529
[11]	Lin Y, Harries AD, Kumar AMV, et al. Management of diabetes mellitus-tuberculosis: a guide to the essential practice. Paris: International Union Against Tuberculosis and Lung Disease, 2019.
[12]	Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J, 2015,46(6):1563-1576. doi: 10.1183/13993003.01245-2015. doi: 10.1183/13993003.01245-2015 URL pmid: 26405286
[13]	Wang JY, Lee MC, Shu CC, et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months? Chest, 2015,147(2):520-528. doi: 10.1378/chest.14-0918. doi: 10.1378/chest.14-0918 URL pmid: 25255302
[14]	Liu Q, Li W, Xue M, et al. Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis. Sci Rep, 2017,7(1):1090. doi: 10.1038/s41598-017-01213-5. URL pmid: 28439071
[15]	Ronacher K, van Crevel R, Critchley JA, et al. Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 2: Underlying Biologic Mecha-nisms. Chest, 2017,152(1):174-180. doi: 10.1016/j.chest.2017.02.032. doi: 10.1016/j.chest.2017.02.032 URL pmid: 28434937
[16]	Huaman MA, Kryscio RJ, Fichtenbaum CJ, et al. Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis. Epidemiol Infect, 2017,145(7):1363-1367. doi: 10.1017/S0950268817000279. doi: 10.1017/S0950268817000279 URL pmid: 28202093
[17]	Chung WS, Lin CL, Hung CT, et al. Tuberculosis increases the subsequent risk of acute coronary syndrome: a nationwide population-based cohort study. Int J Tuberc Lung Dis, 2014,18(1):79-83. doi: 10.5588/ijtld.13.0288. URL pmid: 24365557
[18]	Sheu JJ, Chiou HY, Kang JH, et al. Tuberculosis and the risk of ischemic stroke: a 3-year follow-up study. Stroke, 2010,41(2):244-249. doi: 10.1161/STROKEAHA.109.567735. doi: 10.1161/STROKEAHA.109.567735 URL pmid: 20035070
[19]	Faurholt-Jepsen D, Range N, PrayGod G, et al. Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania. Trop Med Int Health, 2013,18(7):822-829. doi: 10.1111/tmi.12120. doi: 10.1111/tmi.12120 URL pmid: 23648145
[20]	Reed GW, Choi H, Lee SY, et al. Impact of diabetes and smoking on mortality in tuberculosis. PLoS One, 2013,8(2):e58044. doi: 10.1371/journal.pone.0058044. doi: 10.1371/journal.pone.0058044 URL pmid: 23469139
[21]	van Crevel R, Dockrell HM, TANDEM Consortium. TANDEM: understanding diabetes and tuberculosis. Lancet Diabetes Endocrinol, 2014,2(4):270-272. doi: 10.1016/S2213-8587(14)70011-7. doi: 10.1016/S2213-8587(14)70011-7 URL pmid: 24703039
[22]	Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008,359(15):1577-1589. doi: 10.1056/NEJMoa0806470. doi: 10.1056/NEJMoa0806470 URL pmid: 18784090
[23]	Mushtaq A. Tuberculosis in diabetes: insidious and neglected. Lancet Respir Med, 2019,7(6):483. doi: 10.1016/S2213-2600(19)30119-5. doi: 10.1016/S2213-2600(19)30119-5 URL pmid: 31003965
[24]	Lachmandas E, Eckold C, Böhme J, et al. Metformin Alters Human Host Responses to Mycobacterium tuberculosis in Healthy Subjects. J Infect Dis, 2019,220(1):139-150. doi: 10.1093/infdis/jiz064. doi: 10.1093/infdis/jiz064 URL pmid: 30753544
[25]	Tseng CH. Metformin Decreases Risk of Tuberculosis Infection in Type 2 Diabetes Patients. J Clin Med, 2018,7(9):264. doi: 10.3390/jcm7090264. doi: 10.3390/jcm7090264 URL
[26]	Pan SW, Yen YF, Kou YR, et al. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment. Chest, 2018,153(6):1347-1357. doi: 10.1016/j.chest.2017.11.040. doi: 10.1016/j.chest.2017.11.040 URL pmid: 29253553
[27]	Vrieling F, Ronacher K, Kleynhans L, et al. Patients with Concurrent Tuberculosis and Diabetes Have a Pro-Atherogenic Plasma Lipid Profile. EBioMedicine, 2018,32:192-200. doi: 10.1016/j.ebiom.2018.05.011. doi: 10.1016/j.ebiom.2018.05.011 URL pmid: 29779698
[28]	Pan SC, Chen CC, Chiang YT, et al. Health Care Visits as a Risk Factor for Tuberculosis in Taiwan: A Population-Based Case-Control Study. Am J Public Health, 2016,106(7):1323-1328. doi: 10.2105/AJPH.2016.303152. doi: 10.2105/AJPH.2016.303152 URL pmid: 27196655
[29]	Zhang Q, Xiao H, Sugawara I. Tuberculosis complicated by diabetes mellitus at shanghai pulmonary hospital, china. Jpn J Infect Dis, 2009,62(5):390-391. URL pmid: 19762992
[30]	Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis, 2006,43(7):848-854. doi: 10.1086/507543. doi: 10.1086/507543 URL pmid: 16941365
[31]	Sun H, Scott DO. Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics. Chem Biol Interact, 2011,194(2/3):159-167. doi: 10.1016/j.cbi.2011.08.011. doi: 10.1016/j.cbi.2011.08.011 URL
[32]	Riza AL, Pearson F, Ugarte-Gil C, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol, 2014,2(9):740-753. doi: 10.1016/S2213-8587(14)70110-X. doi: 10.1016/S2213-8587(14)70110-X URL pmid: 25194887
[33]	Kewcharoenwong C, Prabowo SA, Bancroft GJ, et al. Gliben-clamide Reduces Primary Human Monocyte Functions Against Tuberculosis Infection by Enhancing M2 Polarization. Front Immunol, 2018,9:2109. doi: 10.3389/fimmu.2018.02109. doi: 10.3389/fimmu.2018.02109 URL pmid: 30283449
[34]	Critchley JA, Restrepo BI, Ronacher K, et al. Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 1: Epidemiology and Clinical Management. Chest, 2017,152(1):165-173. doi: 10.1016/j.chest.2017.04.155. doi: 10.1016/j.chest.2017.04.155 URL pmid: 28434936
[35]	van Crevel R, Koesoemadinata R, Hill PC, et al. Clinical management of combined tuberculosis and diabetes. Int J Tuberc Lung Dis, 2018,22(12):1404-1410. doi: 10.5588/ijtld.18.0340. doi: 10.5588/ijtld.18.0340 URL pmid: 30606312